Boehringer puts a tar­get on Hu­mi­ra, says push­ing it off for­mu­la­ries is nec­es­sary

For biosim­i­lars to win, Ab­b­Vie has to lose, ac­cord­ing to Boehringer In­gel­heim.

The Ger­man drug­mak­er on Wednes­day said that its goal of get­ting more up­take for Hu­mi­ra biosim­i­lars will re­quire push­ing Ab­b­Vie’s drug off of PBM for­mu­la­ries. Boehringer’s high-con­cen­tra­tion, cit­rate-free for­mu­la­tion of its Hu­mi­ra biosim­i­lar Cyl­te­zo won FDA ap­proval on Wednes­day.

The com­pa­ny’s for­mu­la­ry push fol­lows a sig­nif­i­cant uptick in mar­ket pen­e­tra­tion by San­doz’s Hu­mi­ra biosim­i­lar, thanks to a new part­ner­ship with CVS Health that cut Ab­b­Vie’s Hu­mi­ra from its spot on ma­jor na­tion­al for­mu­la­ries. Boehringer is now look­ing to make a sim­i­lar move, and it al­ready has a re­la­tion­ship with Cigna’s Ever­north to re­duce out-of-pock­et costs with its biosim­i­lar.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER